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Abstract
Objective: Outcome after aneurysmal subarachnoid hemorrhage (SAH)
depends critically on delayed cerebral ischemia (DCI) – a process driven
primarily by vascular events including cerebral vasospasm, microvessel throm-
bosis, and microvascular dysfunction. This study sought to determine the
impact of postconditioning – the phenomenon whereby endogenous protection
against severe injury is enhanced by subsequent exposure to a mild stressor –
on SAH-induced DCI. Methods: Adult male C57BL/6 mice were subjected to
sham, SAH, or SAH plus isoflurane postconditioning. Neurological outcome
was assessed daily via sensorimotor scoring. Contributors to DCI including
cerebral vasospasm, microvessel thrombosis, and microvascular dysfunction
were measured 3 days later. Isoflurane-induced changes in hypoxia-inducible
factor 1alpha (HIF-1a)-dependent genes were assessed via quantitative polymer-
ase chain reaction. HIF-1a was inhibited pharmacologically via 2-methoxyestra-
diol (2ME2) or genetically via endothelial cell HIF-1a-null mice (EC-HIF-1a-
null). All experiments were performed in a randomized and blinded fashion.
Results: Isoflurane postconditioning initiated at clinically relevant time points
after SAH significantly reduced cerebral vasospasm, microvessel thrombosis,
microvascular dysfunction, and neurological deficits in wild-type (WT) mice.
Isoflurane modulated HIF-1a-dependent genes – changes that were abolished in
2ME2-treated WT mice and EC-HIF-1a-null mice. Isoflurane-induced DCI pro-
tection was attenuated in 2ME2-treated WT mice and EC-HIF-1a-null mice.
Interpretation: Isoflurane postconditioning provides strong HIF-1a-mediated
macro- and microvascular protection in SAH, leading to improved neurological
outcome. These results implicate cerebral vessels as a key target for the brain
protection afforded by isoflurane postconditioning, and HIF-1a as a critical
mediator of this vascular protection. They also identify isoflurane postcondi-
tioning as a promising novel therapeutic for SAH.
Introduction
Delayed cerebral ischemia (DCI) is the most common
and most severe form of secondary brain injury to
develop after aneurysmal subarachnoid hemorrhage
(SAH). Occurring after a stereotypical delay (peak inci-
dence 4–12 days post ictus), it is thus the most likely to
be amenable to therapeutic intervention.1 The primary
pathophysiological events implicated in DCI involve the
cerebrovasculature. Cerebral vasospasm, felt by many to
be a principal driver of DCI, is characterized by delayed
and severe narrowing of large cerebral arteries.2 This
striking vascular pathology has been repeatedly identified
as an independent risk factor for both brain infarction
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and poor outcome after SAH.2–4 Several additional vascular
processes are also linked to DCI, including microvascular
autoregulatory dysfunction and microvessel thrombosis.2
In fact, many believe a combination of these pathological
vascular events are required to ultimately produce DCI (for
review, see Macdonald2).
Cerebral conditioning describes the phenomenon
wherein the brain’s endogenous protective mechanisms
against a severe injury can be induced by exposure to a
mildly stressful stimulus.5,6 Initial investigations into cere-
bral conditioning focused on its beneficial effects on neuro-
nal survival and function; research in recent years, however,
has made it clear that the cerebrovasculature (as well as glial
cells) is also an important effector of the resulting injury-
tolerant phenotype.7 Given that the pathophysiological
events that underlie DCI are primarily vascular (vasospasm,
microvascular dysfunction, and microvessel thrombosis), a
conditioning-based strategy capitalizing on endogenous
protective cascades that robustly protect the cerebrovascula-
ture (as well as neurons and glia) would represent a power-
ful, novel intervention for SAH-induced DCI.
We previously applied such a strategy to SAH,8 showing
that hypoxic preconditioning (i.e., exposure to hypoxia
prior to SAH) prevented vasospasm and markedly
improved neurological outcome, and that this protection
depended critically on endothelial nitric oxide synthase
(eNOS), a molecule whose dysregulation after SAH is
known to contribute to vasospasm,9 microvascular dys-
function,10 and microvessel thrombosis.11 As a follow-up
to this proof-of-concept study, we next turned our atten-
tion toward translating this concept to a post-SAH condi-
tioning paradigm. Given the strong experimental evidence
that volatile anesthetics when delivered not only as a pre-
conditioning stimulus12–16 but also as a postconditioning
therapeutic agent17,18 provide robust protection against
acute brain injury, we began our translational studies in
SAH by examining the neurovascular protection afforded
by isoflurane postconditioning.
Herein, we characterize the breadth and extent of the
protection afforded by isoflurane postconditioning in SAH
– a unique acute cerebrovascular condition where delayed
vascular pathological events play a dominant role in deter-
mining long-term patient outcome.2 We also begin to elu-
cidate the molecular mediator(s) of this neurovascular
protective response. In particular, we critically examined
vascular endothelium-derived hypoxia-inducible factor
1alpha (HIF-1a) in the protection afforded by isoflurane
postconditioning in SAH, given that this molecule has been
frequently implicated in the protection afforded by condi-
tioning-based strategies for ischemic brain injury19–27 and
has recently been linked (though not causally established)
to the protection afforded by isoflurane postconditioning
in experimental focal cerebral ischemia.28 To obtain direct,
causal data, we employed complementary HIF-1a-directed
interventions including pharmacologic inhibition of HIF-
1a via 2-methoxyestradiol (2ME2) administration and
genetic inhibition of vascular endothelial HIF-1a knockout
mice via a Cre-Lox approach.
Materials and Methods
Ethical statement
All experimental protocols were approved by the Animals
Studies Committee at Washington University in St. Louis
and complied with the NIH Guide for the Care and Use
of Laboratory Animals and with Washington University
Department of Comparative Medicine guidelines.
Study design
Allocation of animals to a given experiment and experi-
mental subgroup was performed randomly prior to each
experiment: one experimenter numbered tails and another
experimenter assigned mice according to these numbers.
All data were collected by experimenters blinded to exper-
imental group. Each experiment included a minimum of
three independent replications (i.e., cohorts subjected to
surgery on separate days, with every experimental group
represented in each cohort).
Experimental animals
Experimental animals were housed in an AAALAC-accredited
facility in temperature- and humidity-controlled rooms with
a 12-h light–dark cycle. Mice were housed five to a cage and
had ad libitum access to laboratory chow and tap water. A
total of 261 mice were used at 12–14 weeks of age (24–30 g):
188 male C57BL/6 mice (Jackson Laboratory, Bar Harbor,
ME) and 67 male endothelial cell HIF-1a null (EC HIF-1a/
); the latter were bred by crossing Tie2-Cre and HIF-1afl/fl
transgenic mice lines (both on C57BL/6 background; both
purchased from Jackson Laboratory) as described29: Tie2-Cre-
positive, HIF-1afl/fl mice were used. In addition, a total of six
male mice derived from crossing Tie2-Cre and ROSA26
reporter mice (background: 129X1/SvJ; Jackson Laboratory)
were used to assess cell-specific expression of Tie2-Cre:
tomato-red fluorescence is changed to green fluorescence with
Cre expression. Only male mice were used due to known neu-
roprotective effects of estrogen.30
Sample sizes
When comparing vasospasm, cortical microthrombosis,
and neurological outcome, based on our previous studies8
we estimated 80% power to detect a 20% difference
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between groups with N = 14 per group based on a
one-way analysis of variance (ANOVA) model at a signifi-
cance of 5%. When comparing microvascular reactivity
and quantitative real-time polymerase chain reaction
(qPCR), based on previous studies31 and the literature32,33
we estimated 80% power to detect a 25% difference
between groups with N = 5–8 per group based on a
one-way ANOVA model at a significance level of 5%.
Experimental procedures
Endovascular perforation SAH
Endovascular perforation SAH was performed per estab-
lished protocol.8 Briefly, a 5–0 blunted nylon suture was
advanced from the left external carotid into the internal
carotid artery and advanced distally to the point of feeling
resistance at its bifurcation into the anterior and middle
cerebral arteries (MCA). For SAH, the suture was
advanced further to cause perforation. For sham, the
suture was removed without advancement. Mice were
allowed to recover in a heated incubator and then
returned to their home cages. Surgeries were performed
in the late morning and early afternoon in the Animal
Surgery Core at Washington University.
Isoflurane postconditioning
Isoflurane postconditioning was performed in an anesthetic
induction chamber, as described with modification.34
Briefly, mice were placed in the chamber perfused with 2%
isoflurane in room air for 1 h; temperature was continu-
ously maintained via a homeothermic blanket. Controls
were placed in the same chamber perfused only by room
air. In experiments assessing isoflurane-induced transcrip-
tional changes, these same parameters were used. In a sub-
set of mice, physiological parameters including arterial pH,
pCO2, pO2, hematocrit, and hemoglobin were assessed via
a femoral artery catheter in three experimental groups –
sham surgery, SAH surgery, SAH surgery + isoflurane
postconditioning (1 h of 2% isoflurane in room air begin-
ning 1 h after SAH surgery). These parameters were
assessed 2 h after sham or SAH surgery in all groups.
Gross neurological outcome
Gross neurological outcome was assessed in the morning
prior to surgery and daily thereafter via sensorimotor scor-
ing per established protocol.8 Briefly, a motor score (0–12;
comprising spontaneous activity, symmetry of limb move-
ment, climbing, and balance and coordination) and a
sensory score (4–12; comprising proprioception plus vibris-
sae, visual, and tactile responses) were added together.
SAH-induced DCI
SAH-induced DCI was assessed 3 days after surgery according
to three components: cerebral vasospasm was assessed per
established protocol8 via pressure-controlled casting with gela-
tin–India ink solution and measurement of the proximal
MCA. Second, microvascular reactivity was assessed as per
established protocol.31 Briefly, a closed cranial window was
made to allow visualization of leptomeningeal arterioles; vaso-
dilation to three stimuli was examined: physiological hyper-
capnia; superfusion of the endothelium-dependent
vasodilator acetylcholine (ACh, 100 lmol/L); and superfusion
of the endothelium-independent vasodilator S-Nitroso-N-ace-
tylpenicillamine (SNAP; 500 lmol/L, both Sigma-Aldrich, St.
Louis, MO). Third, cortical microvessel thrombosis was assessed
via 3,30-diaminobenzidine (DAB) staining for fibrinogen as
described with modification.35 Briefly, following transcardial
perfusion with heparinized Phosphate buffered saline (PBS),
brains were removed fixed in 4% paraformaldehyde, and
sliced coronally at 50 lm. Six coronal sections from the genu
of the corpus callosum to the end of the dorsal hippocampus
were incubated with blocking buffer (0.1% Triton-X100, 0.2%
dry mild, and 1% bovine serum albumin [BSA] in PBS) on a
shaker for 1 h, then incubated with rabbit antifibrinogen anti-
body (1:1000; Abcam, Cambridge, MA) at 4°C overnight.
After wash with PBS, sections were incubated with goat–anti-
rabbit biotinylated secondary antibody (1:1000; BioRad, Her-
cules, CA) for 1 h, incubated with VECTASTAIN Elite ABC
Kit solution (Vector Laboratories, Inc., Burlingame, CA), and
DAB solution. Sections were then mounted on a slide glass
and coverslipped. Photographic images of fibrinogen immu-
nostaining were taken using a Nikon Eclipse 600ME digital
video microscopy system and MetaMorph imaging software
(Molecular Devices, Sunnyvale, CA). Percent coverage of fibr-
ogen-immunoreactive areas of parietal cortex (3 fields/sec-
tion; 6 sections/mouse) ipsilateral to SAH injury was
determined using the threshold function in ImageJ software
(NIH, Bethesda, MD).
The HIF inhibitor 2ME2
The HIF inhibitor 2ME2 (Sigma St. Louis, MO, USA) was
administered at a dose of 15 mg/kg IP once daily (vehicle:
normal saline), with the first dose given prior to isoflurane
exposure or surgery. This dose was chosen based on a pre-
vious report36 showing its efficacy in preventing HIF-med-
iated transcriptional effects in adult rodent brain. 2ME2 is
known to inhibit both HIF-1a and HIF-2a.37
Quantitative real-time PCR
qPCR was performed as described.32 Briefly, following trans-
cardial perfusion with heparinized PBS, cortex was rapidly
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frozen on dry ice followed by extraction of messenger RNA
using TRIzol (Life Technologies, Grand Island, NY) and
reverse transcription (of 2 lg mRNA) with the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Foster,
CA). qPCR of HIF-1a and HIF-2a transcriptional targets was
performed using the ABI 7500 in default mode with SYBR
Green Master Mix (Applied Biosystems) using the following
primers (Integrated DNA Technologies, Coralville, IA): HIF-
1a – forward GAACATCAAGTCAGCAACGTG, reverse
TTTGACGGATGAGGAATGGG; erythropoietin (EPO)
– forward GAGGTACATCTTAGAGGCCAAG, reverse TCT
TCCACCTCCATTCTTTTCC; glucose transporter 1 (GL
UT1) – forward GATTGGTTCCTTCTCTGTCGG, reverse
CCCAGGATCAGCATCTCAAAG; BCL2/adenovirus E1B
19 kd-interacting protein (BNIP3) – forward ACCACAAGA
TACCAACAGAGC, reverse CGACTTGACCAATCCCA-
TATCC; and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) – forward CTTTGTCAAGCTCATTTCCTGG,
reverse TCTTGCTCAGTGTCCTTGC. mRNA levels were
calculated relative to GAPDH via the DCt method and are
expressed relative to na€ıve controls.
Cre-mediated expression
Cre-mediated expression was assessed by crosses of Tie2-
Cre mice with floxed ROSA26 reporter mice per estab-
lished protocols.38 Briefly, following transcardial perfu-
sion with heparinized PBS, brains were removed and
sliced coronally at 50 lm. Sections were counterstained
with 4’,6-DiAmidino-2-PhenylIndole (DAPI) then
mounted on glass slides and coverslipped with Vecta-
Shield (Vector Laboratories, Burlingame, CA).
Statistical analysis
Data represent individual animals and are expressed as
means  SEM. Following testing for normality, vasospasm,
microthrombosis, microvessel reactivity, and qPCR were ana-
lyzed by ANOVA followed by Tukey’s HSD test. Following
testing for normality, Neuroscore was analyzed by repeated
measures ANOVA followed by Newman–Keuls multiple
comparison. Statistical significance was set at P < 0.05.
Results
Isoflurane postconditioning attenuates SAH-
induced vasospasm, microvessel
thrombosis, and microvascular dysfunction
To determine the temporal window for postcondition-
ing-induced protection, we exposed mice to isoflurane at
various times after SAH surgery. Nonpostconditioned
mice served as controls. All mice subjected to SAH
surgery were found to have SAH at the time of animal
sacrifice; no mice subjected to sham surgery were found
to have SAH at the time of animal sacrifice. Mortality
was not significantly different between groups (nonpost-
conditioned = 6.1%; postconditioned = 6.9%). Substan-
tial DCI protection, however, was noted between
postconditioned and nonpostconditioned mice. Specifi-
cally, SAH-induced vasospasm was eliminated when
postconditioning was initiated 15 min, 1 h, or 3 h after
SAH; this protection was lost when postconditioning
began 6 h after SAH (Fig. 1A and B; P < 0.05, ANOVA).
Given the robust protection seen with postconditioning
starting at 1 h, this time point was used for subsequent
experiments. Other vascular contributors to DCI were
also significantly improved by postconditioning. Exten-
sive cortical microvessel thrombosis was noted in MCA-
territory of the cerebral cortex after SAH, which was
significantly reduced by postconditioning (Fig. 2A and B;
P < 0.05, ANOVA). SAH-induced microvascular
dysfunction was also attenuated by postconditioning
(Fig. 3). Cerebral microvascular function was significantly
impaired after SAH as assessed by responses to physio-
logic hypercapnia, as well as to local application of the
endothelium-dependent and endothelium-independent
dilators ACh and SNAP, respectively, compared to sham
animals. Postconditioning fully restored the vasodilatory
responses to hypercapnia and SNAP (Fig. 3; P < 0.05,
ANOVA). Together, these results show that isoflurane
postconditioning after experimental SAH positively
impacts multiple vascular contributors to DCI. This is
direct evidence that isoflurane postconditioning induces
strong protection of the cerebrovasculature and indicates
this strategy is a novel and promising therapeutic
approach toward ameliorating the devastating effects of
SAH-induced DCI.
Isoflurane postconditioning improves
neurological outcome after SAH
To determine whether the breadth of protection affor-
ded by postconditioning extends from the cerebrovascu-
lature to functional outcomes, neurological status was
assessed before SAH and daily thereafter via sensorimo-
tor scoring. SAH caused significant neurological deficits,
which were markedly attenuated by isoflurane postcon-
ditioning beginning at 15 min, 1 h, or 3 h, but not at
6 h, after ictus (Fig. 4; P < 0.05, repeated measures
ANOVA). The neurovascular protection afforded by iso-
flurane postconditioning was not related to isoflurane-
induced physiological changes, as no significant differ-
ences in arterial pH, pCO2, pO2, O2 saturation, hemat-
ocrit, and hemoglobin were noted across experimental
groups (Table 1).
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Pharmacologic inhibition of HIF prevents
isoflurane’s transcriptional effect and
isoflurane postconditioning’s neurovascular
protection
Next, we sought to determine whether this SAH-tolerant
phenotype is dependent on HIF. Because HIF-1a regula-
tion does not entail an increase in gene transcription
(activation of HIF-1a by hypoxia occurs via inhibition of
HIF-1a degradation by the proteasome; activation of
HIF-1a by nonhypoxic stimuli occurs via increase in HIF-
1a protein translation39), we assessed isoflurane-induced
activation of HIF-1a by quantitating changes to several of
its transcriptional targets via qPCR. In na€ıve wild-type
(WT) mice, isoflurane exposure did not impact HIF-1a
mRNA expression (as expected); however, it significantly
modulated HIF-1a transcriptional targets GLUT1 and
BNIP3 as well as HIF-2a transcriptional target EPO in a
time-dependent manner (Fig. 5A). Administration of
2ME2 (a pharmacologic inhibitor of both HIF-1a and
HIF-2a) significantly attenuated these effects for each
gene (Fig. 5A; P < 0.05, ANOVA). The same dose of
2ME2 eliminated the protection afforded by isoflurane
postconditioning against SAH-induced vasospasm
(Fig. 5B; P < 0.05, ANOVA) and neurological deficits
(Fig. 5C; P < 0.05, repeated measures ANOVA).
Together, these results show that isoflurane modulates
HIF-driven gene transcription, and that pharmacologic
inhibition of this transcriptional response abolishes the
protection against SAH-induced neurovascular dysfunc-
tion afforded by isoflurane postconditioning.
Genetic deletion of endothelial HIF-1a
inhibits isoflurane’s transcriptional effect
and isoflurane postconditioning’s
neurovascular protection
To test our hypothesis that HIF-1a-driven transcriptional
activation in ECs in response to isoflurane postcondition-
ing drives the observed vasculoprotective phenotype, we
Figure 1. Postconditioning eliminates SAH-induced vasospasm. Mice underwent sham surgery; subarachnoid hemorrhage (SAH) surgery; or SAH
surgery followed by isoflurane postconditioning (2% for 1 h, SAH-postC) starting 15 min, 1 h, 3 h, or 6 h after surgery. On post surgery day 3,
pressure-controlled cerebrovascular casting was performed with gelatin–India ink. (A) Representative images of the middle cerebral artery (MCA)
ipsilateral to endovascular perforation. Scale bar = 500 lm. (B) Vessel diameter of the ipsilateral MCA was assessed. N = 6 sham, N = 10 SAH,
N = 16 SAH-postC-150, N = 12 SAH-postC-1 h, N = 14 SAH-postC-3 h, N = 15 SAH-postC-6 h. Data represent mean  SEM. *P < 0.05 versus
sham, #P < 0.05 versus SAH, by repeated measures ANOVA.
ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 329
E. Milner et al. Isoflurane-Induced Vascular Protection in SAH
generated EC-specific HIF-1a-null mice. EC expression of
Cre in our Tie2-Cre mice was verified by crossing them
with ROSA26 reporter mice and examining cerebral
microvascular fluorescence in the brains of their progeny.
As shown in Figure 6, green fluorescence – indicative of
Cre expression – was seen throughout the cerebrovascular
endothelium of Cre-positive mice (Fig. 6Av–viii), but the
endothelium of Cre-negative mice fluoresced red
(Fig. 6Ai–iv). In na€ıve EC HIF-1a/ mice, isoflurane
exposure did not significantly affect transcription of the
HIF-1a targets GLUT1 and BNIP3; in contrast, transcrip-
tion of EPO was significantly increased (Fig. 6B;
P < 0.05, ANOVA), which is consistent with a known
role of vascular HIF-2a (retained in these mice) in regu-
lating EPO.40 Genetic deletion of endothelial HIF-1a
eliminated the protection afforded by isoflurane postcon-
ditioning against SAH-induced vasospasm (Fig. 6C;
P < 0.05, ANOVA) and neurological deficits (Fig. 6D;
P < 0.05, repeated measures ANOVA). Collectively, these
results provide causal evidence that vascular endothelium-
derived HIF-1a is critical for isoflurane’s transcriptional
effect and the neurovascular protection afforded by its
use as a postconditioning treatment in SAH.
Discussion
DCI is the most common and potentially treatable cause
of secondary neurological injury following SAH1; among
patients affected by DCI, up to one-third experience poor
outcome or death.2 A central role of cerebral vasospasm
in DCI is supported by the observations that vasospasm
and DCI coincide temporally3; that DCI-related
Figure 2. Postconditioning attenuates SAH-induced cortical microvessel thrombosis. Mice underwent sham surgery, subarachnoid hemorrhage
(SAH) surgery, or SAH surgery followed 1 h later by isoflurane postconditioning (2% for 1 h, SAH-postC). On post surgery day 3, fixed brain
sections were subjected to fibrinogen immunohistochemistry. (A) Representative images of parietal cortex ipsilateral to endovascular perforation.
Scale bar = 100 lm. (B) Cortical microvessel thrombosis was determined as percent coverage of ipsilateral parietal cortex. N = 15 sham, N = 16
SAH, N = 12 SAH-postC. Data represent mean  SEM. *P < 0.05, **P < 0.01 by ANOVA.
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symptoms occur within the territory of spastic arteries in
many patients with vasospasm4; and that targeted endo-
vascular treatment of vasospasm often improves patients’
neurological status.41 Whereas the terms DCI and vaso-
spasm were previously used interchangeably, the last dec-
ade has seen an expanded appreciation for the
contribution of other pathophysiological processes includ-
ing cortical microvessel thrombosis and microvascular
dysfunction to DCI (for review, see Macdonald2). We8
and others5 have hypothesized that SAH may represent
an ideal clinical scenario for a conditioning-based therapy
due to several factors: (1) the predictability of ischemia –
after a stereotypical delay of many days – in a significant
fraction of SAH patients; (2) the severity of DCI and its
contribution to poor patient outcome; and (3) the multi-
factorial nature of DCI that could be positively affected
by a conditioning stimulus.
We thus sought to determine whether postconditioning
– with a clinically relevant stimulus and at clinically rele-
vant time points – could mitigate the deleterious effects
of DCI. Our main findings are as follows: First, we dem-
onstrated that a brief “dose” of isoflurane administered
15 min, 1 h, or 3 h after SAH (but not 6 h later) strik-
ingly attenuated SAH-induced vasospasm and neurologi-
cal deficits. This shows that a clinically relevant paradigm
of isoflurane postconditioning provides strong vascular
protection in SAH and that this protection leads to a sub-
stantial improvement in neurological outcome. Second,
we found that isoflurane postconditioning markedly
attenuated two additional vascular contributors to DCI,
cortical microvessel thrombosis and microvascular dys-
function. This shows that isoflurane provides broad vas-
cular protection – both at the macrovessel level
(vasospasm) and at the microcirculatory level. This
breadth of vascular protection enhances the translational
potential of an isoflurane-based conditioning approach
for SAH. Third, we documented that isoflurane exposure
modified HIF target gene expression and that this tran-
scriptional modulation was prevented by pharmacologic
and genetic inhibition of HIF in an internally consistent
manner. Specifically, pharmacologic inhibition of HIF-1a
and HIF-2a with 2ME2 prevented isoflurane-induced
modulation of all HIF target genes (GLUT1, BNIP3, and
EPO), while selective genetic deletion of HIF-1a in ECs
prevented isoflurane-induced modulation of HIF-1a tar-
get genes (GLUT1 and BNIP3) but not HIF-2a target
genes (EPO).40 Fourth, we demonstrated that both phar-
macologic (2ME2 administration) and genetic inhibition
(selective deletion of HIF-1a in ECs) of HIF-1a reversed
Figure 3. Postconditioning reverses SAH-induced microvascular
dysfunction. Mice underwent sham surgery, subarachnoid
hemorrhage (SAH) surgery, or SAH surgery followed 1 h later by
isoflurane postconditioning (2% for 1 h, SAH-postC). On post surgery
day 3, microvessel reactivity of the distal middle cerebral artery (MCA)
was examined through an open cranial window. Pial arteriolar
vasodilatory responses to hypercapnia (CO2), the endothelium-
dependent vasodilator acetylcholine (ACh), and the endothelium-
independent vasodilator S-nitroso-N-acetyl-penicillamine (SNAP) were
assessed. N = 7 per group. Data represent mean  SEM. *P < 0.05
by ANOVA.
Figure 4. Postconditioning improves neurological outcome after SAH.
Mice underwent sham surgery; subarachnoid hemorrhage (SAH)
surgery; or SAH surgery followed by isoflurane postconditioning (2%
for 1 h, SAH-postC) starting 15 min, 1 h, 3 h, or 6 h after surgery.
Neurobehavioral assessment was performed on post surgery days 0–3
via sensorimotor scoring. N = 6 sham, N = 10 SAH, N = 16 SAH-
postC-150, N = 12 SAH-postC-1 h, N = 14 SAH-postC-3 h, N = 15
SAH-postC-6 h (the same animals as were assessed for vasospasm in
Fig. 1). Data represent mean  SEM. *P < 0.05 versus sham,
#P < 0.05 versus SAH, by repeated measures ANOVA and Newman–
Keuls multiple comparison test.
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the neurovascular protective phenotype we identified in
isoflurane postconditioned mice. These data shed new
light on the mechanism by which isoflurane produces
vascular protection against acute cerebrovascular injury –
that is, vascular endothelium-derived HIF-1a is a key
mediator of the robust vascular protection afforded by
isoflurane postconditioning. Taken together, these data
indicate that a clinically relevant paradigm of isoflurane
postconditioning strongly inhibits macro- and microvas-
cular contributors to DCI, that this multifaceted vascular
protection is mediated via EC-derived HIF-1a, and that
the robust vascular protection afforded by isoflurane
postconditioning leads to markedly improved neurologi-
cal outcome after SAH.
Previously, we reported that SAH is amenable to a condi-
tioning strategy: we showed that hypoxic preconditioning
attenuated SAH-induced neurovascular dysfunction in
mice, and that this protection was critically dependent on
eNOS-derived nitric oxide.8 Subsequently, Altay and col-
leagues showed that early brain injury after mouse SAH can
be impacted by isoflurane postconditioning, as cerebral
edema, neuronal cell death, and neurological deficits were
all reduced at 24 h post-SAH.34,42 However, in contrast to
our finding of sustained isoflurane-induced neurovascular
protection at 72 h post-SAH, these investigators noted that
the protection was transient, as reductions in cerebral
edema and neurological deficits were lost at 72 h post-SAH
(neuronal cell death was not examined beyond 24 h). This
discrepancy in the sustainability of isoflurane-induced pro-
tection has a variety of potential explanations including
variations between our respective endovascular perforation
techniques (4–0 vs. 5–0 suture), our neurological assess-
ment scales (6-point vs. 8-point sensorimotor scoring), our
vascular endpoints (blood-brain barrier [BBB] disruption
vs. vasospasm, microvessel thrombosis, and microvascular
dysfunction), or a combination of the above. Regardless,
this study significantly extends upon these initial findings
in several important ways: (1) we demonstrated isoflurane
postconditioning produced sustained neurological protec-
tion in SAH; (2) we found that it protected against three
separate vascular contributors to DCI that act at both the
macrovessel (vasospasm) and microvessel (microvessel
thrombosis and microvascular dysfunction) levels; (3) we
show an extended therapeutic window of opportunity (3 h
post-SAH); and (4) we identified vascular endothelium-
derived HIF-1a as an essential factor in the neurovascular
protection afforded by isoflurane postconditioning.
Table 1. Physiological parameters in arterial blood.
Group n pH pCO2 (mmHg) pO2 (mmHg) Hematocrit (%) Hemoglobin (g/dL)
Sham 4 7.40  0.01 41.5  1.1 90.7  3.4 43.6  0.5 14.2  0.3
SAH 6 7.37  0.01 42.9  1.0 87.9  0.9 44.2  0.5 14.3  0.3
SAH:postC 5 7.39  0.01 41.1  1.9 90.7  4.2 44.1  0.6 14.7  0.2
SAH, subarachnoid hemorrhage.
Figure 5. Hypoxia-inducible factor (HIF)-1 mediates isoflurane-
induced transcription and postconditioning-induced neurovascular
protection after subarachnoid hemorrhage (SAH). (A) Mice were
administered vehicle or the HIF-1 inhibitor 2-methoxyestradiol (2ME2),
exposed to isoflurane (2% for 1 h), sacked at 3 h, 24 h, or 72 h, and
cortical tissue was subjected to quantitative real-time PCR. Data
represent mean  SEM. *P < 0.05 versus na€ıve, #P < 0.05 versus
time-matched isoflurane only by ANOVA. N = 6 mice per group. (B
and C) Mice were administered vehicle and subjected to sham
surgery; were administered vehicle and subjected to SAH surgery
followed 1 h later by isoflurane postconditioning (2% for 1 h, SAH-
postC); or administered 2ME2 and subjected to SAH-postC. On post
surgery day 3, pressure-controlled cerebrovascular casting was
performed with gelatin–India ink (B). Data represent mean  SEM.
*P < 0.05 by ANOVA. Neurobehavioral assessment was performed on
post surgery days 0–3 via Neuroscore (C). N = 8 sham, N = 10 SAH,
N = 10 SAH-postC, N = 9 SAH-postC-2ME2. Data represent
mean  SEM. *P < 0.05 versus sham, #P < 0.05 versus SAH,
‡P < 0.05 versus SAH-postC-veh by repeated measures ANOVA and
Newman–Keuls multiple comparison test.
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Inhalational anesthetic-induced conditioning with
agents such as isoflurane has been reported to produce
robust neuroprotection in a variety of acute cerebrovascu-
lar conditions including cerebral ischemia,12–14 neonatal
hypoxia–ischemia,43,44 and cerebral hemorrhage.15,16 The
majority of these studies have focused on characterizing
and mechanistically understanding the neural protection
afforded by volatile anesthetics – that is, how anesthetics
such as isoflurane protect against neuronal cell death,
ischemic brain injury, and neurological deficits. Recently,
however, Chi and colleagues45 examined whether the
brain protection afforded by isoflurane is, in part, due to
vascular protection induced via specific vascular-related
molecular cascades. They found that rats subjected to iso-
flurane preconditioning had improved regional cerebral
blood flow in the ischemic cortex 1 and 3 h after induc-
tion of focal cerebral ischemia. They also showed that
this improved regional cerebral blood flow was abolished
with pharmacologic inhibition of inducible nitric oxide
synthase (iNOS). Whether similar vascular protection is
afforded when isoflurane is administered in a postcondi-
tioning paradigm or when it is applied to other acute
cerebrovascular conditions such as SAH, however, has yet
to be explored; nor has the upstream molecular inducer
(s) of isoflurane-induced vascular protection been identi-
fied.
Figure 6. Endothelial hypoxia-inducible factor (HIF)-1 mediates isoflurane-induced transcription and postconditioning-induced neurovascular
protection after subarachnoid hemorrhage (SAH). Endothelial cell HIF-1 null (EC HIF-1/) mice were bred using a Cre-lox system. (A) Tie2-Cre
mice were bred to ROSA26 reporter mice. Note green fluorescence in cerebrocortical endothelial cells (indicating Tie2-Cre expression) but not in
other cell types (red) in the brains of the offspring. Scale bar = 500 lm. (B) EC HIF-1/ mice were subjected to normoxia (na€ıve) or isoflurane
(2% for 1 h), sacked at 3 h or 24 h, and cortical tissue was subjected to quantitative real-time PCR. N = 5 mice per group. Data represent
mean  SEM. *P < 0.05 versus na€ıve by ANOVA. n.s. P > 0.05. (C–D) EC HIF-1/ mice underwent sham surgery, SAH surgery, or SAH surgery
followed 1 h later by isoflurane postconditioning (2% for 1 h, SAH-postC). On post surgery day 3, pressure-controlled cerebrovascular casting
was performed with gelatin–India ink. (C) Vessel diameter of the ipsilateral middle cerebral artery was assessed. N = 21 sham, N = 20 SAH,
N = 11 SAH-postC. Data represent mean  SEM. *P < 0.05 by ANOVA. n.s. P > 0.05. (D) Neurobehavioral assessment was performed on post
surgery days 0–3 via Neuroscore. Data represent mean  SEM. *P < 0.05 versus sham by repeated measures ANOVA and Newman–Keuls
multiple comparison test.
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As opposed to the limited understanding of the mecha-
nism(s) by which inhalational anesthetics induce vascular
protection, the cascades by which such agents induce neu-
ronal protection (at least in the setting of cerebral ische-
mia) have been well studied, (for reviews, see Kitano
et al.46 and Wang et al.47) with several lines of evidence
indicating that HIF-1a may play an essential role. Isoflu-
rane increases HIF-1a28,48 and HIF target genes28,48; iso-
flurane protects against oxygen–glucose deprivation-
induced neuronal cell death in a HIF-1a-dependent fash-
ion28; and several strategies for augmenting HIF-1a have
been shown to be reduce neuronal injury and improve
neurological outcome after cerebral ischemia (for review,
see Ratan et al.49) as well as cerebral hemorrhage.50
Importantly, however, a causal role of HIF-1a in the
brain protection afforded by isoflurane has yet to be pro-
ven with in vivo experiments; and the role of HIF-1a in
the vascular protection afforded by isoflurane has yet to
be examined. In this study, we provide such evidence: (1)
We establish that isoflurane-induced protection extends
to SAH, a fundamentally different form of acute cerebro-
vascular injury; (2) We found that this protection is
strongly dependent on the protective effects of isoflurane
on the cerebrovasculature – both at the macro- and mic-
rolevels; and (3) We show through a combination of tar-
geted pharmacologic and genetic approaches that vascular
endothelium-derived HIF-1a is an essential mediator of
the vascular protection afforded by isoflurane postcondi-
tioning in SAH. These results have important implica-
tions. First, they demonstrate that isoflurane
postconditioning – when initiated at a clinically relevant
dose and at clinically relevant time points – is a promis-
ing therapeutic approach to combat SAH-induced DCI.
Second, they provide new evidence that the mechanism
by which isoflurane reduces brain injury after acute cere-
brovascular insults is, in part, via induction of vascular
protection. Third, they provide evidence that HIF-1a is a
key molecular inducer of the vascular protection afforded
by isoflurane. When coupled with the finding of Chi and
colleagues that iNOS is required for isoflurane-induced
vascular protection in ischemic stroke45 and evidence
indicating that iNOS is a downstream genetic target of
HIF-1a,51 these results suggest that HIF-1a-iNOS may be
the molecular cascade by which isoflurane promotes vas-
cular protection in acute brain injury.
Our experimental results are substantiated by recent
studies examining the beneficial effect of cerebral condi-
tioning in patients with acute cerebrovascular conditions.
The first evidence of such a phenomena in cerebrovascu-
lar patients came from Zsuga and colleagues52 who dem-
onstrated that patients with a history of transient
ischemic attacks who later suffer an ischemic stroke have
smaller infarctions and lower rates of in-hospital mortal-
ity than patients without a history of such attacks.52 More
recently, in collaboration with Hoh and colleagues, we
showed that a preconditioning effect may also exist in
SAH patients.53 In this study, we found that SAH patients
with preexisting steno-occlusive cerebrovascular disease
develop significantly less angiographic vasospasm than
those without such disease. Although these reports do not
establish causation, they intriguingly suggest that the
human cerebrovasculature may, in fact, benefit from non-
injurious stressors in ways similar to what has been docu-
mented in animal models.
Results from our study raise several questions that
warrant further investigation. First, by what mechanism
(s) does isoflurane activate HIF-1a in the context of post-
conditioning in SAH? Here, several possibilities exist
including isoflurane upregulation of HIF-1a via phos-
phorylation by phosphatidyl inositol phosphate 3-kinase,
S-nitrosylation by nitric oxide, and reduced hydroxylation
by prolyl hydroxylases (for review, see Hieber et al.54).
Second, by what downstream molecular effector(s) does
HIF-1a reduce the brain’s susceptibility to SAH? One
possibility is that the protection afforded by isoflurane is
the consequence of HIF-1a’s effect on gene expression
and protein synthesis in its cell of origin, the vascular
endothelium. If so, several observations suggest that
eNOS could be the downstream mediator: (1) eNOS is
expressed in vascular ECs and can be modulated by HIF-
1a55; (2) eNOS has been linked to vasospasm,9 microvas-
cular dysfunction,10 and cortical microvessel thrombo-
sis11; and (3) the neurovascular protection afforded by a
different conditioning paradigm (hypoxia 24 h prior to
SAH) is critically dependent on eNOS.8 Another possibil-
ity – though not mutually exclusive from HIF-1a’s effects
on vascular ECs – is that one or more HIF-1a-driven
secreted proteins exert paracrine protective effects on
neighboring cells. Potential target molecules here include
iNOS (which, as mentioned above, has been implicated in
the vascular protection afforded by isoflurane in cerebral
ischemia45) and vascular endothelial growth factor (which
has been previously linked to vasospasm protection56).
Third is the neurovascular protection afforded by post-
conditioning present across SAH model systems (endo-
vascular perforation, cisterna magna injection,
prechiasmatic injection), species (lissencephalic vs. gy-
rencephalic), gender (male vs. female), age (young vs.
old), comorbidities (hypertension, diabetes, etc.), and
outcome measures (short-term vs. long-term)? These
cross-validation experiments are critical if isoflurane ther-
apy is to be considered for translational studies, and are
strongly advocated by the Stroke Therapy Academic
Industry Roundtable.57
Another important issue to be examined is the impact
of HIF-1a upregulation by SAH itself (which several
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groups have documented in various animal models of
SAH58,59) versus that induced by isoflurane postcondi-
tioning as documented in this study. In this instance,
timing, severity, and sustainability of HIF-1a upregulation
and its downstream transcriptional effects may matter
greatly since pharmacologic inhibition of HIF-1a activa-
tion has been shown to be protective or deleterious
depending on the specific experimental conditions in
acute cerebrovascular injury paradigms including ischemic
stroke (for review, see Singh et al.60) and SAH.58,59,61,62
This “double-edged sword” impact of HIF-1a must be
fully understood in the setting of SAH if HIF-1a-based
therapies are to be pursued in translational studies. Alter-
natively, it may be that the therapeutic index for HIF-1a-
directed therapies is too narrow for HIF-1a to be a viable
druggable target, in which case isoflurane itself (or poten-
tially other anesthetic agents with conditioning effects)
may prove a more promising intervention against SAH-
induced DCI.
In conclusion, this study demonstrates that isoflurane
has strong vascular protective effects on SAH, that this
protection produces robust improvement in neurological
outcome after SAH, and that this vascular protective phe-
notype is critically dependent on vascular endothelial cell
HIF-1a-driven gene transcription. The latter raises the
intriguing possibility that HIF-1a is not only a mediator
of vascular protection in SAH but may also be a previ-
ously unrecognized molecular target for the vascular pro-
tection provided by isoflurane postconditioning in other
acute cerebrovascular conditions like ischemic stroke.
These results are especially exciting given that isoflurane
is already FDA approved for use in the SAH patient pop-
ulation and that administration of isoflurane at a clini-
cally applicable dose and at a clinical relevant time point
provided robust protection against several contributors to
SAH-induced DCI. Moreover, the stereotypical delay
between SAH and DCI provides a meaningful therapeutic
window of opportunity for an isoflurane-based postcondi-
tioning strategy. Such a window may also be exploited for
HIF-1a-directed therapies if future studies demonstrate
that such approaches provide similar neurovascular
protection in experimental SAH.
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